The research studies the safety and efficacy of high-dose recombinant human TPO in solid
tumor patients with moderate or severe thrombocytopenia induced by chemotherapy. Patients
with platelet count lower than 50 x 109/L will be enrolled and treated with high-dose rhTPO
(300-600U/kg/day) until the platelets increased by 50 x 109/L compared to the baseline or
above 100 x 109/L. During the study, the blood routine test will be regularly performed
according to the clinical routine (at least once every two days). Finally, the clinical data
will be collected and analyzed to validate the efficacy and safety of high-dose rhTPO
therapy.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University